MiMedx Group Inc
mimedx.comMiMedx Group Inc (NASDAQ: MDXG) is a biologics company that processes and sells placental-tissue allografts and animal-derived wound care products to clinicians treating chronic and hard-to-heal wounds. Revenue is transactional, generated by selling tissue grafts and related products to hospitals, wound care centers, and surgical settings, with distribution through independent sales agents and distributors as well as Group Purchasing Organizations and Integrated Delivery Networks. The company's product portfolio includes EPIFIX, EPICORD, EPICORD Expandable, EPIEFFECT, and AMNIOFIX, with domestic sales accounting for the vast majority of revenue as of the FY2025 10-K filed February 25, 2026. In 2024, the company expanded beyond its historical focus on placental biologics by adding xenograft products, and in 2025 and early 2026 entered agreements with manufacturers of other wound care modalities. The company does not pay cash dividends and carries debt under the Citizens Credit Agreement. EW Healthcare Partners holds a material ownership stake.
Products & Services
Placental allografts (EPIFIX, EPICORD, EPICORD Expandable, EPIEFFECT, AMNIOFIX), xenograft animal-derived wound care products added in 2024, and third-party wound care modalities added via manufacturer agreements in 2025 and early 2026.
Revenue Model
Transactional product sales of tissue allografts and wound care biologics to clinicians and healthcare facilities, distributed through independent sales agents, distributors, Group Purchasing Organizations, and Integrated Delivery Networks.
Customers & Markets
Clinicians and healthcare providers treating chronic wounds (diabetic foot ulcers, venous leg ulcers), surgical specialties including intestinal surgery, wound care centers, and hospital surgical settings. Customer access through Group Purchasing Organizations and Integrated Delivery Networks.
Geographic Exposure
Domestic U.S. sales account for the vast majority of revenue as of the FY2025 filing. International expansion is being pursued, primarily targeting Japan.
Loading...
